Capital Research Global Investors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
VCM
VPM
Capital Research Global Investors's LLY Position: Q1 2026 in Review
Capital Research Global Investors increased its Eli Lilly (LLY) stake by 0.27% in Q1 2026, buying an estimated $66.7M and bringing the position to 24,632,647 shares worth $22.7B. The position accounts for 3.51% of the portfolio, ranked #5.
Capital Research Global Investors first reported a position in LLY in Q2 2013 and has held it in 17 quarters since. The position peaked at $26.4B in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Capital Research Global Investors held 24,632,647 shares of Eli Lilly worth $22.7B as of Q1 2026.
- Capital Research Global Investors bought 65,801 Eli Lilly shares in Q1 2026, an estimated $66.7M.
- Eli Lilly made up 3.51% of Capital Research Global Investors's portfolio in Q1 2026, its #5 holding.
- Capital Research Global Investors first reported a position in Eli Lilly in Q2 2013 and has held it in 17 quarters since.
- Capital Research Global Investors's Eli Lilly position peaked at $26.4B in Q4 2025.
- 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.